» Articles » PMID: 35890334

Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Jul 27
PMID 35890334
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hepatitis B is a critical cause of many serious liver diseases such as hepatocellular carcinoma (HCC). The main challenges in hepatitis B treatment include the rebound of hepatitis B virus (HBV)-related antigen levels after drug withdrawal and the immunosuppression caused by the virus. Herein, we demonstrate that the HBV-related antigen can be effectively inhibited and antiviral immunity can be successfully reactivated through codelivery of the small interfering RNA (siRNA) targeting HBV X protein (HBx) and the plasmid encoding interleukin 12 (pIL-12) to hepatocytes and immune cells. After being treated by the siRNA/pIL-12 codelivery system, HBx mRNA and hepatitis B surface antigen (HBsAg) are dramatically reduced in HepG2.215 cells. More importantly, the downregulated CD47 and programmed death ligand 1 (PD-L1) and the upregulated interferon-β promoter stimulator-1 (IPS-1), retinoic acid-inducible gene-1 (RIG-1), CD80, and human leukocyte antigen-1 (HLA-1) in treated HepG2.215 cells indicate that the immunosuppression is reversed by the codelivery system. Furthermore, the codelivery system results in inhibition of extracellular regulated protein kinases (ERK) and phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) pathways, as well as downregulation of B-cell lymphoma-2 (Bcl-2) and upregulation of p53, implying its potential in preventing the progression of HBV-induced HCC. In addition, J774A.1 macrophages treated by the codelivery system were successfully differentiated into the M1 phenotype and expressed enhanced cytokines with anti-hepatitis B effects such as interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α). Therefore, we believe that codelivery of siRNA and pIL-12 can effectively inhibit hepatitis B virus, reverse virus-induced immunosuppression, reactivate antiviral immunity, and hinder the progression of HBV-induced hepatocellular carcinoma. This investigation provides a promising approach for the synergistic treatment of HBV infection.

Citing Articles

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.

Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.

PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.


Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B.

He W, Zheng Z, Zhao Q, Zhang R, Zheng H Pathogens. 2025; 13(12.

PMID: 39770359 PMC: 11728772. DOI: 10.3390/pathogens13121100.


Emerging roles of liquid-liquid phase separation in liver innate immunity.

Zhang X, Yang Z, Fu C, Yao R, Li H, Peng F Cell Commun Signal. 2024; 22(1):430.

PMID: 39227829 PMC: 11373118. DOI: 10.1186/s12964-024-01787-4.


Editorial for Special Issue: Advanced Technologies for Developing the State-of-the-Art Nanomedicines.

Hu Y, Chen J Pharmaceutics. 2023; 15(7).

PMID: 37514140 PMC: 10383853. DOI: 10.3390/pharmaceutics15071954.


Exploring the potential of treating chronic liver disease targeting the PI3K/Akt pathway and polarization mechanism of macrophages.

Yang Y, Jia X, Qu M, Yang X, Fang Y, Ying X Heliyon. 2023; 9(6):e17116.

PMID: 37484431 PMC: 10361319. DOI: 10.1016/j.heliyon.2023.e17116.


References
1.
Liu L, Hou J, Xu Y, Qin L, Liu W, Zhang H . PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response. PLoS One. 2020; 15(7):e0228302. PMC: 7337294. DOI: 10.1371/journal.pone.0228302. View

2.
Jongsma M, de Waard A, Raaben M, Zhang T, Cabukusta B, Platzer R . The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. 2020; 54(1):132-150.e9. PMC: 8722104. DOI: 10.1016/j.immuni.2020.11.003. View

3.
Fanning G, Zoulim F, Hou J, Bertoletti A . Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019; 18(11):827-844. DOI: 10.1038/s41573-019-0037-0. View

4.
Wang Y, Lin Y, Qiao S, An H, Ma Y, Qiao Z . Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2016; 112:153-163. DOI: 10.1016/j.biomaterials.2016.09.034. View

5.
Han Q, Zhang C, Zhang J, Tian Z . Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS One. 2011; 6(12):e27931. PMC: 3234243. DOI: 10.1371/journal.pone.0027931. View